Thermo Fisher Scientific reaches 20-day high amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Jan 26
Source: 144
Thermo Fisher Scientific Inc (TMO) saw a price increase of 3.01%, reaching a 20-day high during regular trading hours. This upward movement aligns with the broader market context, as the Nasdaq-100 (QQQ) is up 0.87% and the S&P 500 (SPY) is up 0.70%.
The stock's rise is attributed to broad market strength, reflecting positive investor sentiment across the sector. The overall market gains have contributed to TMO's performance, indicating a favorable environment for growth in the life sciences sector.
This upward trend may suggest continued investor confidence in Thermo Fisher's growth prospects, especially as the company operates in a robust market environment that supports its strategic initiatives.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 626.620
Low
580.00
Averages
658.89
High
750.00
Current: 626.620
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
